Value of anti-p53 antibody as a biomarker for hepatocellular carcinoma: Evidence from a meta-analysis.

ABSTRACT:

Introduction

The incidence of hepatocellular carcinoma (HCC) ranks sixth in the world, but its mortality is the third highest due to the lack of early diagnostic markers. Nowadays, the increase of autoantibody levels has been found in many cancers, and many studies have begun to pay attention to the detection of anti-p53 antibodies in HCC. The purpose of this study is to quantitatively and comprehensively analyze the potential diagnostic value of anti-p53 autoantibodies in HCC METHODS:: English articles up to November 2019 were collected. The overall sensitivity and specificity were calculated. Besides, the positive likelihood ratio, negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and summary receiver operating characteristic curves of the overall diagnostic accuracy

SUBMITTER: Chang Y 

PROVIDER: S-EPMC7447394 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature